Cartagena Protocol on Biosafety (2000) — Treaty Brief

Overview

The Cartagena Protocol on Biosafety (2000) is an international agreement under the Convention on Biological Diversity (CBD) that aims to ensure the safe handling, transport, and use of living modified organisms (LMOs) resulting from modern biotechnology. Its primary focus is on protecting biodiversity and human health from potential risks posed by LMOs, particularly those crossing international borders. The Protocol establishes a regulatory framework based on the precautionary approach, requiring informed decision-making through risk assessments and advance informed agreements for the transboundary movement of LMOs intended for intentional introduction into the environment (Article 7). It also promotes information sharing, capacity building, and public awareness related to biosafety.

Key obligations

• Advance Informed Agreement (AIA) Procedure: States must obtain consent from the importing country before the first intentional transboundary movement of LMOs intended for release into the environment (Article 7).

• Risk Assessment: Parties are required to conduct scientific risk assessments to evaluate potential adverse effects of LMOs on biodiversity and human health (Article 15).

• Information Sharing: The Protocol mandates the establishment and maintenance of a Biosafety Clearing-House (BCH) to facilitate the exchange of information on LMOs, risk assessments, and national biosafety regulations (Article 20).

• Labeling Requirements: LMOs destined for direct use as food, feed, or processing must be labeled to inform recipients of their modified nature (Article 18).

• Monitoring and Reporting: Parties must monitor the effects of LMOs on biodiversity and report any adverse effects to the Biosafety Clearing-House (Article 16).

• Capacity Building and Technical Assistance: Developed countries are encouraged to provide support to developing countries to implement the Protocol effectively (Article 22).

• Public Awareness and Participation: Parties should promote public awareness, education, and participation concerning the safe use of biotechnology (Article 23).

Signatories and status

The Cartagena Protocol has been widely adopted, with a significant number of parties from both developed and developing countries. Major agricultural exporters and importers such as the European Union member states, Canada, and many Latin American countries are parties to the Protocol, reflecting broad international support for biosafety regulation. The United States, a major producer and exporter of genetically modified organisms (GMOs), is notably not a party to the Protocol, citing concerns about trade restrictions and the Protocol’s potential impact on innovation. Other high-profile non-parties include several countries with emerging biotechnology sectors that have either not ratified or have delayed accession. The Protocol’s ratification pattern shows stronger uptake among developing countries, which often emphasize biosafety as critical to protecting their rich biodiversity and agricultural sectors. The Protocol entered into force in 2003 and continues to be the principal international instrument governing biosafety.

Major controversies

• Interpretation of the Precautionary Approach: One of the central disputes concerns how strictly the precautionary principle should be applied. Some parties advocate for stringent restrictions on LMOs pending conclusive scientific evidence of safety, while others argue for more flexible, science-based risk assessments to avoid unnecessary trade barriers.

• Scope and Coverage of LMOs: Disagreements exist over whether certain products of biotechnology, such as processed foods derived from LMOs or products of newer gene-editing techniques, fall under the Protocol’s regulatory framework. This ambiguity has led to calls for updating definitions and annexes.

• Enforcement and Compliance: The Protocol lacks strong enforcement mechanisms, relying largely on state cooperation and transparency. This has led to concerns about non-compliance and illegal transboundary movements of LMOs, especially in regions with limited regulatory capacity.

• Trade and Sovereignty Tensions: The Protocol’s requirements sometimes clash with World Trade Organization (WTO) rules, leading to tensions between biosafety regulations and trade liberalization commitments. Some countries fear that biosafety measures could be used as disguised trade barriers.

• Withdrawal and Non-Participation: While no major party has formally withdrawn, ongoing resistance by influential countries like the United States limits the Protocol’s universal applicability and complicates global governance of biotechnology.

Recent developments

In the last five years, discussions under the Protocol have increasingly focused on emerging biotechnologies such as gene editing (e.g., CRISPR) and synthetic biology, which challenge existing regulatory frameworks. The Parties have been considering how to address these technologies within the Protocol’s scope, including potential amendments or supplementary guidance. Capacity-building efforts have intensified, with international organizations and donor countries supporting developing nations to strengthen biosafety frameworks and improve risk assessment capabilities.

Additionally, the Protocol’s meetings have emphasized enhancing the Biosafety Clearing-House to improve transparency and data sharing. There has also been growing attention to the Protocol’s role in achieving the Sustainable Development Goals (SDGs), particularly those related to biodiversity conservation, food security, and health.

Why it matters now

As biotechnology rapidly evolves and the global trade in LMOs expands, the Cartagena Protocol remains a critical tool for balancing innovation with precaution to protect biodiversity and human health. Its framework helps countries navigate complex scientific, environmental, and trade issues, making it highly relevant for ongoing international negotiations on biosafety and sustainable development. For policymakers, researchers, and delegates, understanding the Protocol is essential for engaging in debates on biotechnology governance and environmental diplomacy.